全球口服固體製劑契約製造市場規模、佔有率、趨勢和成長分析報告（2026-2034）

全球口服固體製劑契約製造市場預計將從2025年的130.8億美元成長至2034年的303.7億美元，2026年至2034年的複合年成長率（CAGR）為9.81%。隨著製藥公司將生產外包給專業的合約研發生產機構（CDMO） ，口服固體製劑（OSD）契約製造市場正經歷顯著成長。片劑和膠囊仍然是最常見的給藥形式，推動了持續的需求。外包能夠最佳化成本、靈活調整生產規模並確保符合全球監管標準。

成長動力包括專利到期後學名藥的生產、小分子藥物研發管線的擴展以及對靈活生產能力的需求。高活性原料藥（API）、連續生產和品管系統的技術進步正在提高效率。製藥公司越來越依賴合約研發生產力機構（CDMO）進行製劑開發和商業化生產。

未來前景穩健，這得益於學名藥和專科藥市場的擴張。新興經濟體可望成為具有成本競爭力的製造地。對自動化、數位化品管和監管合規的投資將增強競爭力。然而，供應鏈中斷和嚴格的監管可能會對業務營運產生影響。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分依據產品類型、應用、最終使用者和地區，將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：我們全面檢驗主要地理區域的市場表現，識別高成長領域和區域趨勢，並深入了解每個區域的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的客製化服務，可根據您的具體需求自訂報告。這包括額外的細分、特定國家/地區的分析、競爭對手分析、客製化資料點或專注於特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球口服固體製劑契約製造市場：依產品分類

• 市場分析、洞察與預測
• 藥片
• 膠囊
• 粉末
• 顆粒
• 其他

第5章：全球口服固體製劑契約製造市場：依機制分類

• 市場分析、洞察與預測
• 即時發布
• 延遲釋放
• 緩釋製劑

第6章：全球口服固體製劑契約製造市場：依最終用途分類

• 市場分析、洞察與預測
• 大公司
• 中型企業/中小企業
• 其他

第7章 全球口服固體製劑契約製造市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Aenova Group
  • Boehringer Ingelheim International GmbH
  • Catalent Inc
  • Corden Pharma International
  • Jubilant Pharmova Limited
  • Lonza
  • NextPharma GmbH
  • Piramal Pharma Solutions
  • Recipharm AB
  • Siegfried Holding AG
  • Thermo Fisher Scientific

The global oral solid dosage contract manufacturing market report size is expected to reach USD 30.37 Billion in 2034 from USD 13.08 Billion in 2025, growing at a CAGR of 9.81% during 2026-2034.The oral solid dosage (OSD) contract manufacturing market has grown significantly as pharmaceutical companies outsource production to specialized contract development and manufacturing organizations (CDMOs). Tablets and capsules remain the most common drug delivery forms, driving sustained demand. Outsourcing enables cost optimization, scalability, and compliance with global regulatory standards.

Growth drivers include patent expirations leading to generic drug production, increasing small-molecule pipelines, and the need for flexible manufacturing capacity. Technological advancements in high-potency APIs, continuous manufacturing, and quality control systems enhance efficiency. Pharmaceutical firms increasingly rely on CDMOs for formulation development and commercial-scale production.

Future prospects are robust, supported by expanding generic and specialty drug markets. Emerging economies offer cost-competitive manufacturing hubs. Investment in automation, digital quality management, and regulatory compliance will strengthen competitiveness. However, supply chain disruptions and stringent regulatory scrutiny may impact operational dynamics.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Product

• Tablets
• Capsules
• Powders
• Granules
• Others

By Mechanism

• Immediate Release
• Delayed Release
• Controlled Release

By End Use

• Large Size Companies
• Medium & Small Size Companies
• Others

COMPANIES PROFILED

• Aenova Group, Boehringer Ingelheim International GmbH, Catalent Inc., Corden Pharma International, Jubilant Pharmova Limited, Lonza, NextPharma GmbH, Piramal Pharma Solutions, Recipharm AB, Siegfried Holding AG, Thermo Fisher Scientific

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Tablets Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Capsules Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Powders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Granules Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: BY MECHANISM 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Mechanism
• 5.2. Immediate Release Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Delayed Release Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Controlled Release Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: BY END USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End Use
• 6.2. Large Size Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Medium & Small Size Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product
  • 7.2.2 By Mechanism
  • 7.2.3 By End Use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product
  • 7.3.2 By Mechanism
  • 7.3.3 By End Use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product
  • 7.4.2 By Mechanism
  • 7.4.3 By End Use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product
  • 7.5.2 By Mechanism
  • 7.5.3 By End Use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product
  • 7.6.2 By Mechanism
  • 7.6.3 By End Use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Aenova Group
  • 9.2.2 Boehringer Ingelheim International GmbH
  • 9.2.3 Catalent Inc
  • 9.2.4 Corden Pharma International
  • 9.2.5 Jubilant Pharmova Limited
  • 9.2.6 Lonza
  • 9.2.7 NextPharma GmbH
  • 9.2.8 Piramal Pharma Solutions
  • 9.2.9 Recipharm AB
  • 9.2.10 Siegfried Holding AG
  • 9.2.11 Thermo Fisher Scientific